Sirius NeoSight and the Centre Léon Bérard join forces by acquiring a stake in the company Sirius NeoSight through the subsidiary Lyon Bérard Innovation (LBI).

This strategic partnership strengthens the close ties between the CLB and Sirius NeoSight, which is housed within the center, with privileged access to platforms, research laboratories and a network of international oncologists. This positioning at the heart of the hospital will also facilitate the ongoing clinical trials in which Sirius NeoSight is fully involved.